Abstract |
The chemokine receptors CXCR1 and CXCR2 present on polymorphonuclear neutrophils (PMN), bind the chemokine CXC ligand 8 (CXCL8)/ interleukin-8 (IL-8), and have a key role in PMN recruitment in inflammation. Based on the structure of reparixin, a small-molecular-weight allosteric inhibitor of CXCR1, we designed a dual inhibitor of CXCR1 and CXCR2 with a longer in vivo half-life, DF2156A. This molecule inhibited human and rat PMN migration in response to CXCR1 and CXCR2 ligands and showed an elimination half-life following i.v. administration, of 19 hours. In a rat model of cerebral ischemia/reperfusion induced by temporary (90 min) middle cerebral artery (MCA) occlusion, DF2156A (8 mg-kg, i.v., at the time of reperfusion) decreased the PMN infiltrate, infarct size and significantly improved neurological function. These results indicate that CXCR1/CXCR2 and their ligands have a role in the inflammatory component of cerebral ischemia, and that these pathways represent an important pharmacological target.
|
Authors | Angela Garau, Riccardo Bertini, Marco Mosca, Cinzia Bizzarri, Roberto Anacardio, Sara Triulzi, Marcello Allegretti, Pietro Ghezzi, Pia Villa |
Journal | European cytokine network
(Eur Cytokine Netw)
Vol. 17
Issue 1
Pg. 35-41
(Mar 2006)
ISSN: 1148-5493 [Print] France |
PMID | 16613761
(Publication Type: Journal Article)
|
Chemical References |
- 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide
- Interleukin-8
- Neuroprotective Agents
- Receptors, Interleukin-8A
- Receptors, Interleukin-8B
- Sulfonamides
|
Topics |
- Allosteric Regulation
- Animals
- Cell Movement
- Humans
- Interleukin-8
(metabolism)
- Ischemic Attack, Transient
(pathology, prevention & control)
- Male
- Neuroprotective Agents
(pharmacokinetics, pharmacology)
- Neutrophils
(metabolism)
- Rats
- Receptors, Interleukin-8A
(antagonists & inhibitors)
- Receptors, Interleukin-8B
(antagonists & inhibitors)
- Sulfonamides
(pharmacokinetics, pharmacology)
|